Alba Therapeutics Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat autoimmune, immune mediated and inflammatory diseases. Alba’s technology provides the ability to transiently, physiologically and reversibly close or open the tight junctions of internal barriers such as the intestinal mucosa and pulmonary epithelia. By altering paracellular permeability across these cell barriers, Alba seeks to develop therapeutic applications ranging from therapies for diseases associated with tight junction dysfunction and autoimmunity to vaccine adjuvancy and drug delivery.
May 20, 2008 - Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
May 16, 2008 - Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
April 3, 2008 - Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
